IDYA News and Press, IDEAYA Biosciences Inc. From 01/13/26

2026-01-13 01:45:57 ET IDEAYA Biosciences, Inc. (IDYA) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 6:45 PM EST... Read the full article on Seeking Alpha For further details see: IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare...

IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 11, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market projected to reach $69.16 billion by 2032 as genomic profiling becomes stan...

IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...

2025-12-16 09:19:08 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 11/14/2025. The 13F portfolio value in...

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma PR Newswire Targeted enrollment of 435 patients to enable potential full a...

IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers PR Newswire Phase 1 dose escalation trial of monotherapy IDE574 expected to begin in 1Q 2026 Targeting to present preclinical data detailing ph...

2025-12-05 17:04:01 ET More on IDEAYA Biosciences IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript Ideaya Biosciences: Primed For Success - Major Eye Cancer Catalyst Weeks Away IDEAYA Biosciences, Inc. (IDYA) Presen...

2025-12-02 17:43:26 ET IDEAYA Biosciences, Inc. (IDYA) Citi Annual Global Healthcare Conference 2025 December 2, 2025 9:00 AM EST... Read the full article on Seeking Alpha For further details see: IDEAYA Biosciences, Inc. (IDYA) Presents at Citi Annual Global Healthcare Conf...

IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types PR Newswire B7H3 and PTK7 is co-expressed in multiple solid tumor types, including lung, colorectal, and head and neck cancers, at ap...